<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775410</url>
  </required_header>
  <id_info>
    <org_study_id>P 0218</org_study_id>
    <nct_id>NCT01775410</nct_id>
  </id_info>
  <brief_title>OptiCal COherence ToMography ABoard InformiNg AtherEctomy</brief_title>
  <acronym>COMBINE</acronym>
  <official_title>A Non-randomized, Multi-center Feasibility Trial of the Avinger Wolverine System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avinger, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avinger, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, non-randomized single arm feasibility trial of the&#xD;
      Wolverine OCT guided atherectomy system.The trial will enroll up to 50 subjects diagnosed&#xD;
      with peripheral vascular disease of the lower extremities.The primary disease must be located&#xD;
      in reference vessel diameters ≥ 2.5 mm which is significant enough to cause moderate to&#xD;
      severe symptoms and warrant vascular intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, non-randomized single arm feasibility trial of the&#xD;
      Wolverine OCT guided atherectomy system. The trial is predominantly descriptive and, as such,&#xD;
      not powered statistically although endpoint comparisons may be made to the published&#xD;
      literature on peripheral atherectomy.&#xD;
&#xD;
      The trial will enroll up to 50 subjects diagnosed with peripheral vascular disease of the&#xD;
      lower extremities. The primary disease must be located in reference vessel diameters ≥ 3.0 mm&#xD;
      which is significant enough to cause moderate to severe symptoms and warrant vascular&#xD;
      intervention. Trial success is focused on short term safety including rates of major adverse&#xD;
      events. An evaluation of efficacy will also be performed and will include an evaluation of&#xD;
      technical success defined as the percent of target lesions that has a residual diameter&#xD;
      stenosis &lt;50% post the Wolverine device alone as assessed by an independent review at the&#xD;
      time of treatment using quantitative angiography or visual estimate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated by sponsor without any AEs to review the device design.&#xD;
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 27, 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With no Major Adverse Events</measure>
    <time_frame>Through 30 day follow-up</time_frame>
    <description>Freedom from major adverse events (MAE) through 30 day follow-up:&#xD;
Clinically driven target lesion revascularization (TLR)&#xD;
Myocardial infarct (MI)&#xD;
Cardiovascular related deaths&#xD;
Unplanned, major index limb amputation&#xD;
Device Related Events:&#xD;
Clinically Significant Perforations&#xD;
Clinically Significant Dissections&#xD;
Clinically Significant Embolus&#xD;
Pseudoaneurysm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success: Percent of Target Lesions That Have a Residual Diameter Stenosis &lt; 50%</measure>
    <time_frame>During interventional procedure</time_frame>
    <description>Technical success is defined as the percent of target lesions that has a residual diameter stenosis &lt; 50% post the Wolverine device alone as assessed by an independent review at the time of treatment using quantitative angiography or visual estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success: Percent of Target Lesions That Have Residual Diameter Stenosis ≤30% Post-Wolverine and Any Other Adjunctive Therapy</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no Procedural Emboli</measure>
    <time_frame>During interventional procedure</time_frame>
    <description>A procedural emboli is defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index (ABI) at 30 Days</measure>
    <time_frame>At 30 days</time_frame>
    <description>Ankle-Brachial Index (ABI) is the ratio of blood pressure in the lower legs to the blood pressure in the arms. It is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.&#xD;
ABI &lt; 0.95 indicates arterial disease; ABI between 0.95 and 1.3 is considered normal (free from significant peripheral artery disease); ABI &gt; 1.3 is abnormal, and suggests calcification of the artery walls and incompressible vessels, indicating severe peripheral vascular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford Classification at 30 Days Post-procedure</measure>
    <time_frame>At 30 days</time_frame>
    <description>Rutherford Classification is a commonly used clinical means for describing the degree of peripheral artery disease. Rutherford Classifications range from Class 0: Asymptomatic, to Class 6: Major Tissue Loss. A lower score is less severe disease and a higher score is more severe disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Atherectomy in Diseased Lower Extremity Arteries</condition>
  <arm_group>
    <arm_group_label>Wolverine System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wolverine System to perform atherectomy</intervention_name>
    <arm_group_label>Wolverine System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old.&#xD;
&#xD;
          2. Patient is a candidate for percutaneous intervention for peripheral vascular disease&#xD;
             in the legs.&#xD;
&#xD;
          3. Patient is willing and able to give informed consent&#xD;
&#xD;
          4. Documented symptomatic atherosclerotic peripheral vascular disease Rutherford&#xD;
             Classification 2-5.&#xD;
&#xD;
          5. Reference vessel lumen proximal to target lesion &gt;2.5 mm in diameter by visual&#xD;
             estimation.&#xD;
&#xD;
          6. Subject has de novo target lesion(s) with stenosis &gt;70% by visual estimation distal to&#xD;
             the profunda femoral artery. No more than 2 lesions may be treated with the Wolverine&#xD;
             device.&#xD;
&#xD;
          7. Target lesion length &lt;10 cm if target lesion &gt;70% and &lt;99% stenosed. If target lesion&#xD;
             a chronic total occlusion (99-100% stenosed), target lesion length &lt;4 cm.&#xD;
&#xD;
          8. Patient is capable of meeting requirements and be present at the follow-up clinic&#xD;
             visits at 30 days.&#xD;
&#xD;
          9. At least one patent tibial run-off vessel at baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is pregnant or breast feeding.&#xD;
&#xD;
          2. Rutherford Class 0 to 1 (asymptomatic and mild claudication).&#xD;
&#xD;
          3. Rutherford Class 6 (critical limb ischemia).&#xD;
&#xD;
          4. Severe calcification of the target lesion.&#xD;
&#xD;
          5. Target lesion with any type of stent or graft.&#xD;
&#xD;
          6. Target lesion in the iliac artery.&#xD;
&#xD;
          7. Target lesion stenosis &lt;70%.&#xD;
&#xD;
          8. Subjects with significant (&gt;70%) occlusive lesions proximal to the target lesion not&#xD;
             successfully treated during the index procedure (upstream disease) and prior to&#xD;
             treatment of the target lesion.&#xD;
&#xD;
          9. Endovascular or surgical procedure performed on the index limb less than or equal to&#xD;
             30 days prior to the index procedure.&#xD;
&#xD;
         10. Planned endovascular or surgical procedure 30 days after the index procedure.&#xD;
&#xD;
         11. Lesion in the contralateral limb requiring intervention during the index procedure or&#xD;
             within 30 days of the index procedure.&#xD;
&#xD;
         12. Subjects with active infections whether they are being currently treated or not.&#xD;
&#xD;
         13. Hemodialysis or GFR &lt;30 mL/min or creatinine level &gt;2.5mg/dL.&#xD;
&#xD;
         14. Evidence or history of intracranial or gastrointestinal bleeding, intracranial&#xD;
             aneurysm, myocardial infarction or stroke within the past 2 months.&#xD;
&#xD;
         15. Evidence or history of aneurysmal target vessel within the past 2 months.&#xD;
&#xD;
         16. History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ&#xD;
             within the past 14 days.&#xD;
&#xD;
         17. Known allergy to contrast agents or medications used to perform endovascular&#xD;
             intervention that cannot be adequately pre-treated.&#xD;
&#xD;
         18. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is&#xD;
             contraindicated.&#xD;
&#xD;
         19. History of heparin-induced thrombocytopenia (HIT).&#xD;
&#xD;
         20. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet&#xD;
             count less than 125,000/mm2 , known coagulopathy, or INR &gt;1.5.&#xD;
&#xD;
         21. Any thrombolytic therapy within 2 weeks of the index procedure.&#xD;
&#xD;
         22. Any clinical and/or angiographic complication attributed to the use of another device&#xD;
             prior to the insertion of the Wolverine into the subject.&#xD;
&#xD;
         23. Subjects or their legal guardians who have not or will not sign the Informed Consent.&#xD;
&#xD;
         24. Subjects who are unwilling or unable to comply with the follow-up study requirements.&#xD;
&#xD;
         25. Participation in any study of an investigational device, medication, biologic or other&#xD;
             agent within 30 days prior to enrollment that is either a cardiovascular study or&#xD;
             could, in the judgment of the investigator, affect the results of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John B Simpson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Avinger, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angiografia de Occidente</name>
      <address>
        <city>Cali</city>
        <state>VAC</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Cardiovascular</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <results_first_submitted>July 14, 2020</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2021</results_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Wolverine System</title>
          <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Wolverine System</title>
          <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Target lesion length in cm</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vessel Luminal diameter in cm</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With no Major Adverse Events</title>
        <description>Freedom from major adverse events (MAE) through 30 day follow-up:&#xD;
Clinically driven target lesion revascularization (TLR)&#xD;
Myocardial infarct (MI)&#xD;
Cardiovascular related deaths&#xD;
Unplanned, major index limb amputation&#xD;
Device Related Events:&#xD;
Clinically Significant Perforations&#xD;
Clinically Significant Dissections&#xD;
Clinically Significant Embolus&#xD;
Pseudoaneurysm</description>
        <time_frame>Through 30 day follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wolverine System</title>
            <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Major Adverse Events</title>
          <description>Freedom from major adverse events (MAE) through 30 day follow-up:&#xD;
Clinically driven target lesion revascularization (TLR)&#xD;
Myocardial infarct (MI)&#xD;
Cardiovascular related deaths&#xD;
Unplanned, major index limb amputation&#xD;
Device Related Events:&#xD;
Clinically Significant Perforations&#xD;
Clinically Significant Dissections&#xD;
Clinically Significant Embolus&#xD;
Pseudoaneurysm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success: Percent of Target Lesions That Have a Residual Diameter Stenosis &lt; 50%</title>
        <description>Technical success is defined as the percent of target lesions that has a residual diameter stenosis &lt; 50% post the Wolverine device alone as assessed by an independent review at the time of treatment using quantitative angiography or visual estimate</description>
        <time_frame>During interventional procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wolverine System</title>
            <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success: Percent of Target Lesions That Have a Residual Diameter Stenosis &lt; 50%</title>
          <description>Technical success is defined as the percent of target lesions that has a residual diameter stenosis &lt; 50% post the Wolverine device alone as assessed by an independent review at the time of treatment using quantitative angiography or visual estimate</description>
          <units>Percentage of target lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success: Percent of Target Lesions That Have Residual Diameter Stenosis ≤30% Post-Wolverine and Any Other Adjunctive Therapy</title>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wolverine System</title>
            <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success: Percent of Target Lesions That Have Residual Diameter Stenosis ≤30% Post-Wolverine and Any Other Adjunctive Therapy</title>
          <units>Percentage of target lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no Procedural Emboli</title>
        <description>A procedural emboli is defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator.</description>
        <time_frame>During interventional procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wolverine System</title>
            <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Procedural Emboli</title>
          <description>A procedural emboli is defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ankle-Brachial Index (ABI) at 30 Days</title>
        <description>Ankle-Brachial Index (ABI) is the ratio of blood pressure in the lower legs to the blood pressure in the arms. It is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.&#xD;
ABI &lt; 0.95 indicates arterial disease; ABI between 0.95 and 1.3 is considered normal (free from significant peripheral artery disease); ABI &gt; 1.3 is abnormal, and suggests calcification of the artery walls and incompressible vessels, indicating severe peripheral vascular disease.</description>
        <time_frame>At 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wolverine System</title>
            <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
          </group>
        </group_list>
        <measure>
          <title>Ankle-Brachial Index (ABI) at 30 Days</title>
          <description>Ankle-Brachial Index (ABI) is the ratio of blood pressure in the lower legs to the blood pressure in the arms. It is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.&#xD;
ABI &lt; 0.95 indicates arterial disease; ABI between 0.95 and 1.3 is considered normal (free from significant peripheral artery disease); ABI &gt; 1.3 is abnormal, and suggests calcification of the artery walls and incompressible vessels, indicating severe peripheral vascular disease.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rutherford Classification at 30 Days Post-procedure</title>
        <description>Rutherford Classification is a commonly used clinical means for describing the degree of peripheral artery disease. Rutherford Classifications range from Class 0: Asymptomatic, to Class 6: Major Tissue Loss. A lower score is less severe disease and a higher score is more severe disease progression.</description>
        <time_frame>At 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wolverine System</title>
            <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
          </group>
        </group_list>
        <measure>
          <title>Rutherford Classification at 30 Days Post-procedure</title>
          <description>Rutherford Classification is a commonly used clinical means for describing the degree of peripheral artery disease. Rutherford Classifications range from Class 0: Asymptomatic, to Class 6: Major Tissue Loss. A lower score is less severe disease and a higher score is more severe disease progression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Wolverine System</title>
          <description>Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dissection</sub_title>
                <description>Dissection of the vessel wall</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Avinger, Inc.</organization>
      <phone>650 241 7030</phone>
      <email>tlawson@avinger.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

